Daiichi Sankyo– tag –
-
Daiichi Sankyo/AstraZeneca’s Datroway Receives US FDA Approval for First-Line Metastatic TNBC, EMA CHMP Gives Positive Opinion
Chemistry Today USA Overview Datroway (datopotamab deruxtecan), the TROP2-directed DXd ADC co-developed by Daiichi Sankyo and AstraZeneca, has received US FDA approval as a first-line treatment for unresectable or metastatic triple-negat... -
Daiichi Sankyo Leverages AI-Driven Biomarker Discovery with Tempus to Strengthen ADC Clinical Strategy
BioPharm International Japan Overview Daiichi Sankyo has announced a new partnership with AI-driven precision medicine company Tempus to enhance its antibody-drug conjugate (ADC) clinical strategy. This collaboration aims to improve pati... -
Daiichi Sankyo’s DXd ADC Pipeline Advances: ENHERTU Files for HER2-Low/Ultra-Low Breast Cancer, Dato-DXd Gains FDA Breakthrough Therapy for EGFRm NSCLC
Quartr Japan Overview Daiichi Sankyo reported significant progress in its DXd antibody-drug conjugate (ADC) pipeline, with ENHERTU showing efficacy in HER2-low and ultra-low breast cancer, leading to global regulatory submissions. Datopo... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
Daiichi Sankyo & AstraZeneca’s Datroway Approved in EU as Only TROP2-Directed Medicine with Overall Survival Benefit for 1st-Line Metastatic TNBC Patients Ineligible for Immunotherapy
Business Wire USA Overview Datroway, a TROP2-directed antibody-drug conjugate (ADC) by Daiichi Sankyo and AstraZeneca, received EU approval for first-line treatment of metastatic triple-negative breast cancer (TNBC) patients not eligible... -
Daiichi Sankyo & AstraZeneca’s Enhertu Plus Pertuzumab Recommended for EU Approval as 1st-Line Treatment for HER2-Positive Metastatic Breast Cancer, Achieves 44% Risk Reduction in Phase III
Daiichi Sankyo Press Release Japan Overview The EMA's CHMP has recommended Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for approval as a first-line treatment for HER2-positive metastatic breast cancer in the EU. This ... -
Daiichi Sankyo’s Early ADC Pipeline Lags Rivals as Cash Flow Nears Peak, Incurs $850M Charges for Underutilized CMO Capacity
BioSpace USA Overview Jefferies analysts suggest Daiichi Sankyo's early-stage antibody-drug conjugate (ADC) pipeline is not keeping pace with rivals, despite the success of Enhertu and Datroway. Enhertu and Datroway are nearing peak reve... -
AstraZeneca/Daiichi Sankyo’s Enhertu Receives EU Approval as First Tumor-Agnostic HER2-Directed ADC
AstraZeneca UK Overview AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has received EU approval as the first tumor-agnostic HER2-directed therapy for patients with previously treated HER... -
Daiichi Sankyo and AstraZeneca’s Gastric Cancer ADC Receives Positive EMA CHMP Opinion for Approval
European Medicines Agency (EMA) Europe Overview The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval for an antibody-drug conjugate (ADC) develo... -
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da...
12